09 May 2019
Visiongain has launched a new pharma report Indian Pharmaceutical Market Report : Infectious Disease, Cardiovascular, Gastrointestinal, Respiratory, Pain Relief / Analgesics, Diabetes, Vitamins/ Minerals/ Nutrients, Dermatology, CNS, Gynaecology, Generic, OTC, Patented, Biosimilar, Leading Companies.
The Indian pharmaceuticals market is estimated to have reach $28.8bn in 2018 and is expected to grow at a CAGR of 16.6% in the first half of the forecast period. The market for cardiovascular medication is the fastest growing segment of the Indian pharmaceutical market, followed by the anti-infective segment.
The lead analyst of the report commented "Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses. Greater patient awareness and confidence will allow more people to self-medicate, driving growth in the OTC segment of the market, whilst patent expiries will drive growth in both the generic and biosimilar segments of the market.
Finally, a far more favourable patent environment, along with a number of government initiatives to encourage innovation in India will spur growth for patented pharmaceutical products as Indian companies invest more of their resources into R&D."
Leading companies featured in the report include Abbott Healthcare Private Limited (Abbott India), Cadila Healthcare Limited, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Limited, Lupin and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.
15 September 2022
The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.